Compounds enhancing human sperm motility identified using a high-throughput phenotypic screening platform
Gruber, Franz S.; Johnston, Zoe C.; Norcross, Neil R.; Georgiou, Irene; Wilson, Caroline; Read, Kevin D.

Published in:
Human Reproduction

DOI:
10.1093/humrep/deac007

Publication date:
2022

Licence:
CC BY

Document Version
Publisher's PDF, also known as Version of record

Link to publication in Discovery Research Portal

Citation for published version (APA):
Gruber, F. S., Johnston, Z. C., Norcross, N. R., Georgiou, I., Wilson, C., Read, K. D., Gilbert, I. H., Swedlow, J. R., Martins da Silva, S., & Barratt, C. L. R. (2022). Compounds enhancing human sperm motility identified using a high-throughput phenotypic screening platform. *Human Reproduction*, 37(3), 466-475. Advance online publication. https://doi.org/10.1093/humrep/deac007

General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain.
• You may freely distribute the URL identifying the publication in the public portal.

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Compounds enhancing human sperm motility identified using a high-throughput phenotypic screening platform

Franz S. Gruber, Zoe C. Johnston, Neil R. Norcross, Irene Georgiou, Caroline Wilson, Kevin D. Read, Ian H. Gilbert, Jason R. Swedlow, Sarah Martins da Silva, and Christopher L.R. Barratt

STUDY QUESTION: Can a high-throughput screening (HTS) platform facilitate male fertility drug discovery?

SUMMARY ANSWER: An HTS platform identified a large number of compounds that enhanced sperm motility.

WHAT IS KNOWN ALREADY: Several efforts to find small molecules modulating sperm function have been performed but none have used high-throughput technology.

STUDY DESIGN, SIZE, DURATION: Healthy donor semen samples were used and samples were pooled (3–5 donors per pool). Primary screening was performed singly; dose–response screening was performed in duplicate (using independent donor pools).

PARTICIPANTS/MATERIALS, SETTING, METHODS: Spermatozoa isolated from healthy donors were prepared by density gradient centrifugation and incubated in 384-well plates with compounds (6.25 μM) to identify those compounds with enhancing effects on motility. Approximately 17000 compounds from the libraries, ReFRAME, Prestwick, Tocris, LOPAC, CLOUD and MMV Pathogen Box, were screened. Dose–response experiments of screening hits were performed to confirm the enhancing effect on sperm motility. Experiments were performed in a university setting.

MAIN RESULTS AND THE ROLE OF CHANCE: From our primary single concentration screening, 105 compounds elicited an enhancing effect on sperm motility compared to dimethylsulphoxide-treated wells. Confirmed enhancing compounds were grouped based on their annotated targets/target classes. A major target class, phosphodiesterase inhibitors, were identified, in particular PDE10A inhibitors as well as number of compounds not previously known to enhance human sperm motility, such as those related to GABA signalling.

LARGE SCALE DATA: N/A.

LIMITATIONS, REASONS FOR CAUTION: Although this approach provides data about the activity of the compound, it is only a starting point. For example, further substantive experiments are necessary to provide a more comprehensive picture of each compound’s activity, the effect on the kinetics of the cell populations and subpopulations, and their potential mechanisms of action. Compounds have been tested with prepared donor spermatozoa, incubated under non-capacitating conditions, and only incubated with compounds for a relatively short period of time. Therefore, the effect of compounds under different conditions, for example in whole semen, for longer incubation times, or using samples from patient groups, may be different and require further study. All experiments were performed in vitro.

© The Author(s) 2022. Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
**WIDER IMPLICATIONS OF THE FINDINGS**: This phenotypic screening assay identified a large number of compounds that increased sperm motility. In addition to furthering our understanding of human sperm function, for example identifying new avenues for discovery, we highlight potential compounds as promising start-point for a medicinal chemistry programme for potential enhancement of male fertility. Moreover, with disclosure of the results of screening, we present a substantial resource to inform further work in the field.

**STUDY FUNDING/COMPETING INTEREST(S)**: This study was supported by the Bill and Melinda Gates Foundation, Scottish Funding Council and Scottish Universities Life Science Alliance. C.L.R.B. is Editor for RBMO. C.L.R.B. receives funding from Chief Scientists Office (Scotland), ESHRE and Genus PLC, consulting fees from Exscientia and lecture fees from Cooper Surgical and Ferring. S.M.d.S. is an Associate Editor of *Human Reproduction*, and an Associate Editor of *Reproduction and Fertility*. S.M.d.S. receives funding from Cooper Surgical and British Dietetic Society. No other authors declared a COI.

**Key words**: drug discovery / sperm motility / high-throughput screening / spermatozoa / subfertility

**Introduction**

Sperm dysfunction is the single most common cause of infertility. However, there is an absence of new diagnostic tools and non-medically assisted reproduction (MAR) based treatments for the subfertile man (Barratt et al., 2017; De Jonge and Barratt, 2019). A fundamental obstacle is the relative paucity of knowledge of the production, formation, maturation and physiological functions of both the normal and dysfunctional spermatozoon. There is an urgent need to address this knowledge gap to formulate appropriate diagnostic assays, develop rational therapies and understand how external factors, such as the environment, influence these processes (Barratt et al., 2021).

Although some progress has been made in our understanding of the workings of the mature spermatozoon using tools such as proteomics, electrophysiology and imaging, one area in which there has been minimal progress is the development of an effective high-throughput screening (HTS) system using motile human spermatozoa (Martins da Silva et al., 2017). Current methods for assessment of sperm quality are time-consuming and inappropriate for high-throughput drug discovery (Schiffer et al., 2014; Tardif et al., 2014). One way around this has been to utilize HTS assays with surrogate measures of sperm function such as intracellular calcium concentration $[\text{Ca}^{2+}]$ (Schiffer et al., 2014; Martins da Silva et al., 2017). Although informative, these do not directly assess cell function and have key limitations. For example, $[\text{Ca}^{2+}]$ should not be used as a surrogate of sperm motility, as a number of compounds can generate an increase in $[\text{Ca}^{2+}]$ but have no significant effect on motility (Martins da Silva et al., 2017; McBrinn et al., 2019). To provide a transformative leap in understanding an HTS system for the assessment of quantitative motility is necessary. Recently, a phenotypic platform has been developed which examined human sperm motility in a high-throughput manner (Gruber et al., 2020; Johnston et al., 2022).

Although this HTS system has been used to identify potential compounds for male contraception, i.e. those having a negative effect on human sperm function, it can conversely be used to uncover elements of sperm cell biology and function, and to identify compounds that enhance sperm function. For example, it allows for large scale screening of not only approved drugs, target-class specific libraries (such as ion channels, kinase inhibitors) but also large libraries of chemically diverse lead-like small molecules that could provide the starting point for medicinal chemistry. In this study, we utilized this HTS system to examine six libraries incorporating ~17,000 compounds with the dual aim of furthering our understanding of human sperm function and, generating possible starting points for a medicinal chemistry programme for potential enhancement of male fertility.

**Materials and methods**

**Experimental design**

We used an HTS screening platform to assess the motility of live human spermatozoa. The platform and its development are described in detail in Gruber et al. (2020) and summarized below in brief. The platform was used to screen six compound libraries for their enhancing effects on motility. Whilst we have developed a screening module for detection of the acrosome reaction using flow cytometry (Gruber et al., 2020), this was not examined in this study in order to increase throughput and focus on compounds affecting motility. The HTS system and experimental design are illustrated in Fig. 1.

**Selection and preparation of spermatozoa**

Semen samples were obtained from volunteer donors. Written consent was obtained from each donor in accordance with the Human Fertilization and Embryology Authority (HFEA) Code of Practice (version 8) under local ethical approval (13/ES/0091) from the Tayside Committee of Medical Research Ethics B. Donors had no known fertility problems and normal sperm concentrations, motility and semen characteristics according to World Health Organisation (WHO) criteria (2010). Samples were obtained by masturbation, after sexual abstinence of 2–5 days, and delivered to the research laboratory within 1 h of production. Samples were allowed to liquify at 37°C for 15–30 min prior to preparation by discontinuous density gradient centrifugation (DGC). Gradients were prepared using 80% and 40% Percoll (Sigma Aldrich, UK) diluted with non-capacitation media (Mesna Essential Medium Eagle Sigma M3024), supplemented with HEPES, sodium lactate and sodium pyruvate to achieve concentrations previously described (Tardif et al., 2014).

For initial screening, prepared donor spermatozoa (80% fraction) were routinely pooled to create screening batches of three to five donars to reduce donor-to-donor variability. After preparation by DGC and pooling into screening batches, cells were incubated for 3 h at 37°C under non-capacitating conditions, as described previously (Gruber et al., 2020).

**The high-throughput screening system**

Full details of the HTS system, and its development, are discussed by Gruber et al. (2020). In brief, screening batches of cells were transferred to a robotic platform (HighRes Biosolutions Inc.) and maintained during the screen at 37°C. Assay-ready 384-well plates, containing...
compounds were prepared prior to the screen, and filled with ~10,000 spermatozoa (20 µl) per well using a liquid handling system (MultiDrop Combi, ThermoFisher). These plates were incubated for 10 min prior to imaging. The HTS system utilized a Yokogawa CV7000 Cell Voyager high-throughput microscope to record time-lapse images from two positions in each well. An adaptation of a tracking algorithm, Trackpy v0.4.1 (Allan et al., 2018), was utilized to track individual spermatozoa within each well and obtain kinematic parameters. Within the compound-test plates, dimethylsulphoxide (DMSO) was used as the vehicle control. Compounds in the plates were allocated at random.

### Libraries screened

The Pathogen box (generously provided by Medicines for Malaria Venture (MMV), https://www.mmv.org/mmv-open/pathogen-box/about-pathogen-box) is a small repurposing library assembled to screen against rare and neglected tropical diseases containing ~400 diverse, drug-like molecules with demonstrated biological activity against different pathogens.

The CeMM Library of Unique Drugs (CLOUD) purchased from Enamine (https://enamine.net/hit-finding/compound-collections/bioreference-compounds/the-comprehensive-drug-collection-cloud) is a set of 263 small molecules representing the target and chemical space of FDA-approved drugs that has been used for drug repurposing. Tocris compound library (Tocris, Bristol, UK, https://www.tocris.com/products/tocriscrerun_5840) comprises 1280 biologically active small molecule compounds.

LOPAC®1280LOPAC (Library of Pharmacologically Active Compounds https://www.sigmaaldrich.com/life-science/cell-biology/bioactive-small-molecules/lopac1280-navigator.html) comprises a bio-logically annotated collection of inhibitors, receptor ligands, pharma-developed tools and approved drugs which impact many signalling pathways and covers all major drug target classes (1280 compounds).

Prestwick Chemical Library (http://www.prestwickchemical.com/libraries-screening-lib-pcl.html) comprising 1280 off patent drugs with
high chemical and pharmacological diversity as well as known bioavailability and safety in humans (12 800 compounds).

ReFRAME (Repurposing, Focused Rescue, and Accelerated Medchem) consists of ~12 000 approved drugs, in-development small molecules and bio-active compounds in the initial library and was constructed as a library for potential drug repurposing (Janes et al., 2018). The advantages of using this library was the potential to identify chemical compounds that are already approved for other indications or have undergone (or currently undergoing) clinical trials or have IND (Investigational New Drug) approval, hence potentially accelerating the progress towards a safe and effective enhancer of motility. CALIBR kindly provided up to 1% of hits for subsequent dose–response experiments. Only the structures of confirmed hits were unblinded. We also received a further 950 compounds, which were added at a later stage to the ReFRAME collection (termed Reframe supplement).

**Data normalization and hit confirmation**

All steps were performed as previously described (Gruber et al., 2020). In summary, data from every compound well were normalized to those from in-plate DMSO controls (wells containing the same amount of DMSO as compound wells). Two positions were recorded in every well and the average of those positions was used for calculating % of control = (VCL median/DMSO median) × 100, where curvilinear velocity (VCL) median is the median of all sperm tracks (immotile, non-progressively motile, progressively motile) in each test well and DMSO median is the median of all 16 DMSO control wells on the corresponding plate. Hits from the primary screening were chosen based on percentage change compared to the control: 40% (for ReFRAME first batch, MMV Pathogenbox) or 20% (for LOPAC, CLOUD, Tocris, Prestwick, ReFRAME Supplement).

Hit compounds were examined in subsequent dose–response experiments. These consisted of two independent experiments utilizing different biological material (i.e. pooled spermatozoa samples from at least three different donors in each experiment). A compound was only identified as having a positive effect if it was confirmed in these dose–response experiments. Dose–response curves consisting of a series of 8-points with 3-fold dilution (with 10 μM top concentration) were fitted using the DR4PL (four-parameter logistic fit) package in R from which ECx (half-maximum effective concentration of × % effect) was estimated.

**Hit analysis**

Chemical space was visualized by generating Morgan fingerprints using RDKit (radius = 2, bits = 2048) and using UMAP (Uniform Manifold Approximation and Projection) (McInnes et al., 2018) for dimensionality reduction. Physico-chemical properties were calculated using RDKit (https://www.rdkit.org) and KNIME (Berthold et al., 2008).

**Results**

In order to find compounds that positively enhance sperm motility, we used an HTS platform (Fig. 1A), to screen ~17 000 compounds comprising a variety of small molecule libraries (Fig. 1B). Primary hits were identified based on percentage effect relative to DMSO control. These limits varied among the libraries and produced a hit rate between 0.3% and 1.9% (Table I). Primary hit compounds were confirmed in subsequent dose–response experiments and, in total 105 compounds were identified as confirmed hits (Supplementary Table SI), with moderate to high motility enhancing activity (Table I, Fig. 2A, Supplementary Table SI). Motility enhancing compounds shift the VCL of the population towards faster moving sperm cells compared to DMSO-treated wells (Fig. 2B–E, Supplementary Movie S1). The confirmed hits were annotated (broad definitions based on vendor annotations) to affect a variety of protein target classes (Fig. 3A, Supplementary Table SI).

Some compounds could not be assigned to a clear target class, however, of the annotated compounds, protein kinase inhibitors and phosphodiesterase inhibitors were the most common target classes (Fig. 3A). Another prominent target class were receptor modulators (inhibitor, agonist, antagonist), some of which are related to GABA signalling (Fig. 3A and C, Panel I, Supplementary Table SI).

The most potent hits had sub-micromolar potency and substantial effects on motility (up to 190% compared to DMSO controls (Table II, Supplementary Table SI)). Chemical space visualization (Fig. 3B) reveals that several confirmed hits have similar or identical structures (Fig. 3C). The small molecule libraries used had some

| Library                  | No. of compounds | No. of increaser hits | Hit cut-off | % Hit rate |
|-------------------------|------------------|-----------------------|-------------|------------|
| ReFRAME                 | ~12 000          | 37                    | ~40%        | 0.3        |
| ReFRAME supplement      | ~950             | 9                     | 20%         | 0.9        |
| Prestwick chemical library | 1280            | 4                     | 20%         | 0.3        |
| Tocriscreen plus         | 1280             | 24                    | 20%         | 1.9        |
| LOPAC                   | 1280             | 20                    | 20%         | 1.6        |
| MMV pathogenbox         | 400              | 8                     | 40%         | 2          |
| CLOUD                   | 263              | 3                     | 20%         | 1.1        |
| **Total**               | **17 503**       | **105**               |             | **1.2**    |

1Increase relative to DMSO control.
2Max. 1% resupply.
DMSO, dimethylsulphoxide; MMV, Medicines for Malaria Venture; ReFRAME, Repurposing, Focused Rescue, and Accelerated Medchem.
Figure 2. Primary screening results with examples. (A) Primary screening data from all screened libraries. Data are presented as a percentage of the control, which is defined as a well median VCL (including all sperm tracks) relative to a median VCL of vehicle (DMSO) control wells. Dashed lines represent hit cut-offs for each library. Each dot represents an individual compound and black dots represent hits with motility increase above the cut-off. (B) Example tracks of spermatozoa treated with Torin 2 or DMSO. The colour indicates the track class: IM (immotile), NPM (non-progressively motile) or PM (progressively motile). (C) Fraction of classified sperm tracks and frequency distribution of sperm track VCL of a well-treated with Torin 2. The x denotes a median of 16 DMSO wells in the same 384-well plate. (D) Example tracks of spermatozoa treated with Linsitinib or DMSO. (E) Fraction of classified sperm tracks and frequency distribution of sperm track VCL of a well-treated with Linsitinib. The x denotes a median of 16 DMSO wells in the same 384-well plate. DMSO, dimethylsulphoxide; VCL, curvelinear velocity.

Figure 3. Classification of screening results. (A) Summary of the target classes of compounds confirmed by dose–response experiments. Target classes were identified according to library annotations. The ‘other/unknown’ category is comprised of compounds with no annotation available from the library vendor or unknown mode of action. (B) Chemical space visualization of motility enhancing compounds. Each enhancing compound has been encoded as chemical fingerprint (Morgan Fingerprint) with 2048 bit features. All features have been reduced to two dimensions using UMAP. The colour indicates screening library (left panel) or annotated target class (right panel). (C) Examples of similar hit structures with names and library information related to GABA signalling (Panel 1, also highlighted in B) and mTOR signalling (Panel 2, also highlighted in B). UMAP, Unifold Manifold Approximation and Projection.
overlapping compounds and a number of these were either consistently active (e.g. SCH 58261, Torin2 (Fig. 3C, Panel 2) or Ethaverine) or consistently inactive (e.g. Rolipram, Milrinone or Sildenafil). A small number of compounds, for example Papaverine, were active in one library but not others.

One prominent target class of confirmed hits were phosphodiesterase (PDE) inhibitors (Table II, Figs 3A and 4A). A number of these, TAK-063, JNJ-42396302, RG-7203 and PF-2545920 have an annotation of PDE10A inhibition (Table III, Fig. 4B) and showed sub-micromolar responses (0.04–0.49 μM) in dose–response experiments (Fig. 4B). All annotated PDE10A inhibitors used in this study had an enhancing effect on motility. For all four PDE10A inhibitors, a similar shift of VCL relative to DMSO controls was observed (Fig. 4C) and we observed an increase in the fraction of progressively motile cells (Fig. 4D). We did not detect any enhancing effect of compounds belonging to the methylxanthine class, e.g. IBMX or Pentoxifylline. Annotated PDE inhibitors used in this study are summarized in Supplementary Table SII.

### Discussion

The current study utilized a validated imaging-based screening platform that measures fundamental aspects of human sperm behaviour (Gruber et al., 2020) to screen a collection of chemical libraries comprising ~17,000 approved drugs, clinically tested compounds and annotated chemical tool compounds for their potential to enhance motility. The aim was to further our understanding of human sperm function and generate possible start points for a medicinal chemistry programme for potential enhancement of male fertility.

There are significant challenges in producing a suitable platform for HTS of mature human spermatozoa (see Gruber et al., 2020), and development is always a balance between achieving the necessary high throughput, assay robustness and a detailed assessment of each compound (see Johnston et al., 2022). In these experiments, initial screening was performed under non-capacitating conditions at one concentration (6.25 μM) with compounds being assessed after a relatively short incubation (10–27 min). The data will therefore primarily reflect the use of these conditions and it is possible that other permutations, for example, screening under capacitating conditions, higher concentrations and/or longer incubation times may generate different results. In the current study, when a primary hit was identified, dose–response experiments were undertaken to confirm the hit and provide initial information on activity. Although this approach provides data about the activity of the compound, it is only a starting point. For example, further experiments are necessary to provide a more comprehensive picture of each compound’s activity and the effect on the kinetics of the cell populations and subpopulations and to determine their mechanisms of action (see McBrinn et al., 2019 for examples of such investigations on human spermatozoa).

This study used spermatozoa from selected healthy donors rather than samples from patients. This was because, firstly, the aims of the study were to improve our understanding of the spermatozoon in addition to identifying possible compounds for further investigation; secondly, screening a large number of compounds requires substantial numbers of semen samples and, thirdly, donor samples are relatively homogenous. Future studies, using compounds, could subsequently utilize selected patient groups, e.g. those with oligozoospermia, isolated asthenozoospermia or oligoasthenozoospermia. These patient

| Compound                        | EC₅₀ [μM] | [% of control] | Target action               |
|---------------------------------|----------|----------------|-----------------------------|
| TAK-063                         | 0.04     | 145            | Phosphodiesterase inhibitor |
| RFM-012-216-7                   | 0.14     | 128            | Unknown                     |
| GW 843682X                      | 0.17     | 192            | Protein kinase inhibitor    |
| Torin2                          | 0.22     | 196            | Protein inhibitor           |
| Linsitinib                      | 0.24     | 191            | Receptor inhibitor          |
| Tolafentrine                    | 0.26     | 153            | Phosphodiesterase inhibitor |
| Epeterimod                      | 0.32     | 166            | Unknown                     |
| E6005                           | 0.33     | 151            | Phosphodiesterase inhibitor |
| GABAα2/α3 agonists              | 0.35     | 138            | Receptor agonist            |
| JNJ-42396302                    | 0.39     | 158            | Phosphodiesterase inhibitor |
| NM-702                          | 0.48     | 152            | Phosphodiesterase inhibitor |
| RG-7203                         | 0.49     | 162            | Phosphodiesterase inhibitor |
| Trequinsin hydrochloride        | 0.5      | 143            | Phosphodiesterase inhibitor |
| Dextofisopam                    | 0.54     | 143            | Unknown                     |
| Papaverine                      | 0.55     | 175            | Phosphodiesterase inhibitor |
| LY-3023414                      | 0.56     | 140            | Protein kinase inhibitor    |
| KF 15832                        | 0.61     | 143            | Phosphodiesterase inhibitor |
| STL515575                       | 0.62     | 140            | Unknown                     |
| Carbazeran                      | 0.63     | 146            | Phosphodiesterase inhibitor |

₁Half maximal effective concentration.
Motility enhancing agents discovered by drug screening

Figure 4. Confirmation of PDE10A inhibitor hits. (A) Summary graph of PDE inhibitor classes based on vendor annotation or available information resources (ChEMBL, PubChem, DrugBank). (B) Dose–response curves of four PDE10A inhibitors, with structures and physico-chemical properties. Blue line: four parameter logistic model. ECx, estimated half-maximum concentration. Each dot represents an individual data point, n = 2 for each concentration with data collected from two independent dose–response experiments utilizing different biological material (i.e. pooled spermatozoa samples from different donors in each experiment). Physico-chemical properties are defined as: MW, TPSA and cLogP. Note that no curve/ECx for PF-2545920 is shown due to noisy data at the two highest concentrations. (C) Frequency distributions of sperm VCL of each PDE10A inhibitor shown in (B) at 1.25 μM concentration (blue) compared to DMSO control wells (grey). (D) Fraction of classified sperm tracks for each PDE10A inhibitor at 1.25 μM concentration. The x denotes a median of 16 DMSO wells run in the same 384-well plate. cLogP, computed CrippenLogP; DMSO, dimethylsulphoxide; MW, molecular weight; PDE, phosphodiesterase; TPSA, topological polar surface area; VCL, curvelinear velocity.
The screening platform is complimentary to a reductionist approach. Identification of several PDE inhibitors as confirmed hits in dose--response experiments (discussed below) provide evidence of the robustness of the HTS platform. Several phosphodiesterase inhibitors (PDEis) (e.g. ibudilast, trequinsin hydrochloride and papaverine) have previously been shown to significantly increase human sperm motility, confirming the ability of the HTS platform to identify compounds which are effective at or below concentrations of 6.25 μM. Furthermore, identical or related compounds which were present in two or more libraries were identified. For example, ibudilast was detected as a hit in both the LOPAC and Tocris libraries, and Trequinsin hydrochloride was confirmed in the ReFRAME and Tocris libraries. Another example is Torin2, a small molecule mTOR inhibitor, which was also detected in two libraries (LOPAC and Tocris) along with a structurally related compound (LY-3023414) with annotated activity against mTOR (see Figs 2B and C and 3C, Panel 2). This is intriguing as it has been recently described that in older men, mTORC1 is inhibited in highly motile spermatozoa compared to their defective/immotile counterparts (Silva et al., 2019). For the largest library screened, the ReFRAME set, only 1% of the hits were unblinded, limiting our ability to analyse less active and inactive compounds from this set.

Of the target classes identified, PDE inhibitors (PDEi) account for 18/105 of the compounds found to increase sperm motility. This is not surprising and several of the PDEi hits have been previously identified to increase human sperm motility, e.g. Dipyrimadole, Ibudilast, Trequinsin Hydrochloride and Papaverine (Tardif et al., 2014). Strikingly, a proportion of the PDEi hit compounds are annotated as specific to PDE10A. Although relatively little has been published on the effects of PDE10A inhibitors on human sperm, active PDE10A has been identified (Marechal et al., 2017). Marechal confirmed their findings in additional experiments with the newly available PDE10A inhibitor MP-10 (Marechal et al., 2017). MP-10, also known as Mardepodect or PF-2545920, was a hit in our screen (Supplementary Table SII). Little information is available for the other PDE10A inhibitors but the high representation of PDE10A inhibitors, combined with their apparent potency, could indicate their potential for further investigations for use in fertility treatment and or MAR.

Several PDE inhibitors which have been well documented for their effects on motility parameters of human sperm, including pentoxifylline aminophylline, theophylline, pentoxifylline, caffeine, and 3-Isobutyl-1-methylxanthine (IBMX) did not appear as hits (Supplementary Tables SI and SII), While this might initially be surprising, it is worth noting that initial screening conditions were at 6.25 μM for 10–27 min incubation and the actions of these drugs may require higher doses and/or longer incubation times. IBMX, for example, is used at concentrations from 30 μM to 1 mM (Lefevre et al., 2000; Pons-Regnier et al., 2011; Tardif et al., 2014; Marechal et al., 2017). Similarly, pentoxifylline has been used at 3–4 mM (Tesarki et al., 1992; Burger et al., 2000; Patrizio et al., 2000; Terriou et al., 2000), although conflicting reports have found no improvement in human sperm motility at the same concentrations (Mathieu et al., 1994; Tournaye et al., 1994) and higher concentrations of 10 mM have been used to examine its effects on spermatozoa DNA damage (Banihani et al., 2018). Other such PDE inhibiting compounds included Milrinone, a PDE3 inhibitor shown to effect human spermatozoa motility at 50 μM (Lefevre et al., 2002), and rolipram, a PDE4 inhibitor with effects at 10 μM (Marechal et al., 2017). Sildenafil and its analogue Vardenafil were also screened without appearing as a hit. PDE5 is expressed at low levels in human spermatozoa (Lefevre et al., 2002) and its inhibition, in vitro, using sildenafil can improve sperm motility. However, conflicting studies reported that this effect requires vastly different concentrations. Lefevre et al. (2000) report that an increase in progressive motility required concentrations of at least 100 μM, while Glenn et al. (2007) report an improvement in progressive motility with just 0.67 μM (Lefevre et al., 2000; Glenn et al., 2007).

A substantial advantage of phenotypic screening is that it potentially opens new areas for investigation to improve our understanding of cell function (Johnston et al., 2022). In this screen, in addition to those addressed above, there are several examples that warrant further investigation. For instance, enhancement of sperm motility by Linstinib (Supplementary Movie SI, Fig. 2D–E) that selectively inhibits IGF-1R and the insulin receptor, is in keeping with the recent data of insulin modulating human sperm survival (Aitken et al., 2021). Another novel consistent finding was that modulation of γ-Aminobutyric acid-GABA resulted in an increase in sperm motility (Supplementary Table SI). While there is significant literature on the role of GABA in induction of the acrosome reaction there is little relating to human sperm motility. In the current data, GABAα2/α3 agonist and NS1 1394 (a GABAα receptor modulator) significantly increased sperm motility. Both are selective positive allosteric modulators of GABAα receptors, albeit working on different GABAα receptor subtypes. Usually, they are inert in the absence of GABA or an equivalent agonist. Moreover, TP003 and U90042, also GABAα receptor agonists, were identified. More detailed experiments examining modulation of GABA and associated receptor complexes will uncover as yet undetermined biology related to human sperm motility.

In summary, using a novel HTS, we identified a large number of compounds that increased sperm motility. In addition to furthering our understanding of human sperm function, for example identifying new avenues for discovery such as the role of GABA in sperm motility, we highlighted PDE10A inhibitors as promising starting point for a medicinal chemistry programme for potential enhancement of male fertility. Moreover, with full disclosure of the results of screening (Supplementary Table SI), we present a detailed resource to inform further work in the field.

**Table III Summary table of confirmed phosphodiesterase (PDE) inhibitors.**

| Compound    | EC₅⁰ (μM)¹ | [% of control] |
|-------------|------------|---------------|
| TAK-063     | 0.04       | 145           |
| JNJ-42396302| 0.39       | 158           |
| RG-7203     | 0.49       | 162           |
| PF-2545920  | n.d.²      | 130           |

¹Half maximal effective concentration.
²EC₅₀ not determined.
Supplementary data

Supplementary data are available at Human Reproduction online.

Data availability

The data underlying this article are available in the article and in its online supplementary material.

Acknowledgements

We are very grateful to all members of the research team for their invaluable assistance. We also want to thank all the volunteer sperm donors who took part in this study and members of the research group for recruitment. We want to thank Dr David Mortimer and Dr Sharon Mortimer for their helpful insights into comparisons with the CASA system. Thanks go to Dr Steve Publicover for critical reading of the manuscript. Thanks are also due to NPSC lab members for help, particularly John Raynor for engineering support. We thank Mitch Hull, Emily Chen and Kelli Kunen at CALIBR for their help in library plating, logistics and supply of ReFRAME data. We would also like to thank Medicines for Malaria Venture (MMV) for providing pathogenbox reagents.

Authors’ roles

F.S.G. performed the sperm preparation, HTS screening, and processing of the data. F.S.G., Z.C.J. and C.L.R.B. analysed and interpreted the data. S.M.d.S., I.H.G. and K.D.R. designed the study, assisted with interpretation of the data and originally obtained funding. All authors contributed to the construction, writing and analysis of data. All authors approved the final manuscript.

Funding

Funding was provided by Bill and Melinda Gates Foundation (INV-007117). NPSC was established with funding from the Scottish Funding Council and Scottish Universities Life Science Alliance.

Conflict of interest

C.L.R.B. is Editor for RBMO; C.L.R.B. receives funding from Chief Scientists Office (Scotland), ESHRE and Genus PLC, consulting fees from Exscenta and lecture fees from Cooper Surgical and Ferring. S.M.d.S. is an Associate Editor of Human Reproduction, and an Associate Editor of Reproduction and Fertility. S.M.d.S. receives funding from Cooper Surgical and British Dietetic Society. No other authors declared a COI.

References

Aitken RJ, Curry BJ, Shokri S, Pujianto DA, Gavrilouk D, Gibb Z, Whiting S, Connaughton HS, Nixon B, Salamonsen LA et al. Evidence that extrapancreatic insulin production is involved in the mediation of sperm survival. Mol Cell Endocrinol 2021; 526: 111193.

Allan DB, Caswell T, Keim NC, van der Wel CM. soft-matter/trackpy: Trackpy v0. 4.2. 2019. https://doi.org/10.5281/zenodo.3492186 (17 January 2022, date last accessed).

Banihani SA, Abu-Allahayaa RF, Amarın ZO, Alzoubi KH. Pentoxifylline increases the level of nitric oxide produced by human spermatozoa. Andrologia 2018; 50: e12859.

Barratt CLR, Björndahl L, De Jonge CJ, Lamb DJ, Osorio Martini F, McLachlan R, Oates RD, van der Poel S, St John B, Sigman M et al. The diagnosis of male infertility: an evidence of the evidence to support the development of global WHO guidance-challenges and future research opportunities. Hum Reprod Update 2017; 23: 660–680.

Barratt CLR, De Jonge CJ, Anderson RA, Eisenberg ML, Garrido N, Rautakallio Hokkanen S, Krausz C, Kimmins S, O’Bryan MK, Pacey AA et al. A global approach to addressing the policy, research and social challenges of male reproductive health. Hum Reprod Open 2021; 2021: hoab009.

Berthold MR, Cebron N, Dill F, Gabriel TR, Köttet T, Meinl T, Ohl P, Sieb C, Thiel K, Wiswedel B. KNIME: the Konstanz information miner. In: Preissach C, Burkhardt H, Schmidt-Thieme L, Decker R (eds). Data Analysis, Machine Learning and Applications Studies in Classification, Data Analysis, and Knowledge Organization. Berlin, Heidelberg: Springer, 2008.

Burger M, Sikka SC, Bivalacqua TJ, Lamb DJ, Hellstrom WJG. The effect of sildenafil on human sperm motion and function from normal and infertile men. Int J Impot Res 2000; 12: 229–234.

De Jonge C, Barratt CLR. The present crisis in male reproductive health: an urgent need for a political, social, and research roadmap. Andrology 2019; 7: 762–768.

Glenn DRJ, McVicar CM, McClure N, Lewis SEM. Sildenafil citrate improves sperm motility but causes a premature acrosome reaction in vitro. Fertil Steril 2007; 87: 1064–1070.

Gruber FS, Johnston ZC, Barratt CLR, Andrews PD. A phenotypic screening platform utilising human spermatozoa identifies compounds with contraceptive activity. eLife 2020; 9: e51739.

James J, Young ME, Chen E, Rogers NH, Burgstaller-Muelbacher S, Hughes LD, Love MS, Hull MV, Kuhlen KL, Woods AK, et al. The ReFRAME library as a comprehensive drug repurposing library and its application to the treatment of cryptosporidiosis. Proc Natl Acad Sci USA 2018; 115: 10750–10755.

Johnston ZC, Gruber FS, Brown SG, Norcross NR, Swedlow J, Gilbert IH, Barratt CLR. High-throughput phenotypic screening of the human spermatozoon. Reproduction 2022; 163: R1–R9.

Lefèvre L, de Laminarde E, Gagnon C. Presence of cyclic nucleotide phosphodiesterases PDE1A, existing as a stable complex with calmodulin, and PDE3A in human spermatozoa.1. Biol Reprod 2002; 67: 423–430.

Lefèvre L, Laminarde ED, Gagnon C. The cyclic GMP-specific phosphodiesterase inhibitor, sildenafil, stimulates human sperm motility and capacitation but not acrosome reaction. J Androl 2000; 21: 929–937.

Marechal L, Guillemette C, Goupil S, Blondin P, Leclerc P, Richard FJ. Cyclic nucleotide phosphodiesterases in human spermatozoa and seminal fluid: presence of an active PDE10A in human spermatozoa. Biochim Biophys Acta Gen Subj 2017; 1861: 147–156.

Martins da Silva SJ, Brown SG, Sutton K, King LV, Ruso H, Gray DW, Wyatt PG, Kelly MC, Barratt CLR, Hope AG. Drug
discovery for male subfertility using high-throughput screening: a new approach to an unsolved problem. *Hum Reprod* 2017;**32**:974–984.

Mathieu C, Eccochar R, Lormage J, Cordonier H, Guérin JF. Variability of the response to pentoxifylline in vitro in infertile normozoospermic and asthenozoospermic patients. *Arch Androl* 1994;**33**:39–49.

McBrinn RC, Fraser J, Hope AG, Gray DW, Barratt CLR, Martins da Silva SJ, Brown SG. Novel pharmacological actions of trequinsin hydrochloride improve human sperm cell motility and function. *Br J Pharmacol* 2019;**176**:4521–4536.

McInnes L, Healy J, Melville J. UMAP: uniform manifold approximation and projection for dimension reduction. ArXiv e-prints 1802.03426 2018.

Patrizio P, Liu Y, Sonek GJ, Berns MW, Tadir Y. Effect of pentoxifylline on the intrinsic swimming forces of human sperm assessed by optical tweezers. *J Androl* 2000;**21**:753–756.

Pons-Rejraji H, Artonne C, Sion B, Bruignon F, Canis M, Janny L, Grizard G. Prostasomes: inhibitors of capacitation and modulators of cellular signalling in human sperm. *Int J Androl* 2011;**34**:568–580.

Schiffer C, Müller A, Egeberg DL, Alvarez L, Brenker C, Rehfeld A, Frederiksen H, Wäschle B, Kaupp UB, Balbach M et al. Direct action of endocrine disrupting chemicals on human sperm. *EMBO Rep* 2014;**15**:758–765.

Silva JV, Cabral M, Correia BR, Carvalho P, Sousa M, Oliveira PF, Fardilha M. mTOR signaling pathway regulates sperm quality in older men. *Cells* 2019;**8**:629.

Tardif S, Madamidola OA, Brown SG, Frame L, Lefievre L, Wyatt PG, Barratt CL, Martins Da Silva SJ. Clinically relevant enhancement of human sperm motility using compounds with reported phosphodiesterase inhibitor activity. *Hum Reprod* 2014;**29**:2123–2135.

Terriou P, Hans E, Giorgetti C, Spach JL, Salzmann J, Urrutia V, Roulier R. Pentoxifylline initiates motility in spontaneously immotile epididymal and testicular spermatozoa and allows normal fertilization, pregnancy, and birth after intracytoplasmic sperm injection. *J Assist Reprod Genet* 2000;**17**:194–199.

Tesarik J, Mendoza C, Carreras A. Effects of phosphodiesterase inhibitors caffeine and pentoxifylline on spontaneous and stimulus-induced acrosome reactions in human sperm. *Fertil Steril* 1992;**58**:1185–1190.

Tournaye H, Janssens R, Verheyen G, Camus M, Devroye P, Van Steirteghem A. An indiscriminate use of pentoxifylline does not improve in-vitro fertilization in poor fertilizers. *Hum Reprod* 1994;**9**:1289–1292.